Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.

ABSTRACT:

Importance

Among patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate, a treatment sequence initiated with biosimilar disease-modifying antirheumatic drugs (DMARDs) provides better clinical efficacy compared with conventional synthetic DMARDs recommended by current treatment guidelines; but its cost-effectiveness evidence remains unclear.

Objective

To evaluate the cost-effectiveness of the treatment sequence initiated with biosimilar DMARDs after failure with methotrexate vs leflunomide and inform formulary listing decisions.

Design, setting, and participants

This economic evaluation's cost-effectiveness analysis was performed at a Hong Kong public institution using the Markov disease transition model to simulate the lifetime disease

SUBMITTER: Peng K 

PROVIDER: S-EPMC11208978 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature